EMEmmanuelle Massouridès

Emmanuelle Massouridès

*This is an algorithmically generated author record based on publicly available information.

Emmanuelle Massouridès has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dp412e : une nouvelle isoforme embryonnaire humaine de la dystrophine

    by Emmanuelle Massouridès

    La dystrophie musculaire de Duchenne (DMD) est une myopathie dévastatrice récessive liée au chromosome X. Cette pathologie est due à la présence de mutations dans le gène DMD codant pour la dystrophine. Le rôle de cette protéine est encore l’objet de nombreuses interrogations et elle pourrait être impliquée dans le développement de la DMD in utero. Les cellules souches pluripotentes humaines (hPSCs) traitées par le BMP4 (bone morphogenetic protein 4) nous ont permis d’étudier les premières étapes de la myogenèse dans un contexte normal et DMD.De façon inattendue, les hPSCs traitées par le BMP4 expriment un transcrit long DMD à un niveau similaire à celui observé dans le muscle squelettique adulte. Ce transcrit possède un exon 1 spécifique et non traduit identifié par 5’RACE PCR dont la séquence est conservée uniquement dans un sous-groupe d’anthropoïdes comprenant l’Homme. L’isoforme de la dystrophine correspondante est caractérisée par un domaine tronqué de fixation à l’actine à l’extrémité N-terminale. Cette protéine de 412 kD a été détectée par Western blot dans des hPSCs normales traitées par le BMP4 ainsi que dans des corps embryoïdes. Suite à des analyses extensives démontrant que son expression était restreinte aux toutes premières étapes de la différenciation, cette nouvelle isoforme a été nommée ‘Dp412e’.Cette étude valide l’utilisation des hPSCs pour analyser les étapes précoces du développement humain dans un contexte normal et pathologique et a conduit à la découverte d’une nouvelle isoforme embryonnaire humaine de la dystrophine de 412 kD. L’étude de la régulation et des fonctions associées à cette nouvelle isoforme contribuera à mieux comprendre la physiopathologie de la DMD et les défauts développementaux potentiels. Le modèle inductible par le BMP4, simple, rapide et robuste, procurant une grande quantité de transcrits longs DMD et la protéine correspondante, est déjà bien adapté aux approches de criblage à haut débit et à haut contenu. Une première preuve d’efficacité de ce modèle a d’ailleurs été réalisée avec succès grâce à une modification par saut d’exon du transcrit Dp412e. La disponibilité de cette plateforme cellulaire performante accéléra le développement, la validation et l’amélioration de thérapies géniques DMD.

  • Open Access

    Dystrophin deficiency impairs cell junction formation during embryonic myogenesis

    by Elise Mozin, Emmanuelle Massouridès, Virginie Mournetas, Clémence Lièvre, Audrey Bourdon, Dana L Jackson, Jonathan S Packer, Cole Trapnell, Caroline Le Guiner, Oumeya Adjali, et al.

    Summary: Mutations in the DMD gene lead to Duchenne muscular dystrophy, a severe X-linked neuromuscular disorder that manifests itself as young boys acquire motor functions. DMD is typically diagnosed at 2 to 4 years of age, but the absence of dystrophin negatively impacts muscle structure and function before overt symptoms appear in patients, which poses a serious challenge in the optimization of standards of care. In this report, we investigated the early consequences of dystrophin deficiency during skeletal muscle development. We used single-cell transcriptome profiling to characterize the myogenic trajectory of human pluripotent stem cells and showed that DMD cells bifurcate to an alternative branch when they reach the somite stage. Here, dystrophin deficiency was linked to marked dysregulations of cell junction protein families involved in the cell state transitions characteristic of embryonic somitogenesis. Altogether, this work demonstrates that in vitro , dystrophin deficiency has deleterious effects on cell-cell communication during myogenic development, which should be considered in future therapeutic strategies for DMD.


  • Open Access

    Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne muscular dystrophy

    by Ai Vu Hong, Nathalie Bourg, Peggy Sanatine, Jerome Poupiot, Karine Charton, Evelyne Gicquel, Emmanuelle Massourides, Marco Spinazzi, Isabelle Richard, David Israeli

    Duchenne muscular dystrophy (DMD) is a severe muscle disease caused by impaired expression of dystrophin. Whereas mitochondrial dysfunction is thought to play an important role in DMD, the mechanism of this dysfunction remains to be clarified. Here we demonstrate that in DMD and other muscular dystrophies, a large number of Dlk1-Dio3 clustered miRNAs (DD-miRNAs) are coordinately up-regulated in regenerating myofibers and in the serum. To characterize the biological effect of this dysregulation, 14 DD-miRNAs were simultaneously overexpressed in vivo in mouse muscle. Transcriptomic analysis revealed highly similar changes between the muscle ectopically overexpressing 14 DD-miRNAs and the mdx diaphragm, with naturally up-regulated DD-miRNAs. Among the commonly dysregulated pathway we found repressed mitochondrial metabolism, and oxidative phosphorylation (OxPhos) in particular. Knocking down the DD-miRNAs in iPS-derived skeletal myotubes resulted in increased OxPhos activities. The data suggest that (1) DD-miRNAs are important mediators of dystrophic changes in DMD muscle, (2) mitochondrial metabolism and OxPhos in particular are targeted in DMD by coordinately up-regulated DD-miRNAs. These findings provide insight into the mechanism of mitochondrial dysfunction in muscular dystrophy.


  • Open Access

    Myogenesis modelled by human pluripotent stem cells: a multi‐omic study of Duchenne myopathy early onset

    by Virginie Mournetas, Emmanuelle Massouridès, Jean‐Baptiste Dupont, Etienne Kornobis, Hélène Polvèche, Margot Jarrige, Alan R.L. Dorval, Maxime R.F. Gosselin, Antigoni Manousopoulou, Spiros D. Garbis, et al.

    Background: Duchenne muscular dystrophy (DMD) causes severe disability of children and death of young men, with an incidence of approximately 1/5000 male births. Symptoms appear in early childhood, with a diagnosis made mostly around 4 years old, a time where the amount of muscle damage is already significant, preventing early therapeutic interventions that could be more efficient at halting disease progression. In the meantime, the precise moment at which disease phenotypes arise—even asymptomatically—is still unknown. Thus, there is a critical need to better define DMD onset as well as its first manifestations, which could help identify early disease biomarkers and novel therapeutic targets.Methods: We have used both human tissue‐derived myoblasts and human induced pluripotent stem cells (hiPSCs) from DMD patients to model skeletal myogenesis and compared their differentiation dynamics with that of healthy control cells by a comprehensive multi‐omic analysis at seven time points. Results were strengthened with the analysis of isogenic CRISPR‐edited human embryonic stem cells and through comparisons against published transcriptomic and proteomic datasets from human DMD muscles. The study was completed with DMD knockdown/rescue experiments in hiPSC‐derived skeletal muscle progenitor cells and adenosine triphosphate measurement in hiPSC‐derived myotubes.Results: Transcriptome and miRnome comparisons combined with protein analyses demonstrated that hiPSC differentiation (i) leads to embryonic/foetal myotubes that mimic described DMD phenotypes at the differentiation endpoint and (ii) homogeneously and robustly recapitulates key developmental steps—mesoderm, somite, and skeletal muscle. Starting at the somite stage, DMD dysregulations concerned almost 10% of the transcriptome. These include mitochondrial genes whose dysregulations escalate during differentiation. We also describe fibrosis as an intrinsic feature of DMD skeletal muscle cells that begins early during myogenesis. All the omics data are available online for exploration through a graphical interface at https://muscle‐dmd.omics.ovh/.Conclusions: Our data argue for an early developmental manifestation of DMD whose onset is triggered before the entry into the skeletal muscle compartment, data leading to a necessary reconsideration of dystrophin roles during muscle development. This hiPSC model of skeletal muscle differentiation offers the possibility to explore these functions as well as find earlier DMD biomarkers and therapeutic targets.


  • Open Access

    Myogenesis modelled by human pluripotent stem cells uncovers Duchenne muscular dystrophy phenotypes prior to skeletal muscle commitment

    by Virginie Mournetas, Emmanuelle Massouridès, Jean-Baptiste Dupont, Etienne Kornobis, Hélène Polvèche, Margot Jarrige, Maxime R. F. Gosselin, Antigoni Manousopoulou, Spiros D. Garbis, Dariusz C. Górecki, et al.

    Duchenne muscular dystrophy (DMD) causes severe disability of children and death of young men, with an incidence of approximately 1/5,000 male births. Symptoms appear in early childhood, with a diagnosis made around 4 years old, a time where the amount of muscle damage is already significant, preventing early therapeutic interventions that could be more efficient at halting disease progression. In the meantime, the precise moment at which disease phenotypes arise – even asymptomatically – is still unknown. Thus, there is a critical need to better define DMD onset as well as its first manifestations, which could help identify early disease biomarkers and novel therapeutic targets. In this study, we have used human induced pluripotent stem cells (hiPSCs) from DMD patients to model skeletal myogenesis, and compared their differentiation dynamics to that of healthy control cells by a comprehensive multi-omic analysis. Transcriptome and miRnome comparisons combined with protein analyses at 7 time points demonstrated that hiPSC differentiation 1) mimics described DMD phenotypes at the differentiation endpoint; and 2) homogeneously and robustly recapitulates key developmental steps - mesoderm, somite, skeletal muscle - which offers the possibility to explore dystrophin functions and find earlier disease biomarkers. Starting at the somite stage, mitochondrial gene dysregulations escalate during differentiation. We also describe fibrosis as an intrinsic feature of skeletal muscle cells that starts early during myogenesis. In sum, our data strongly argue for an early developmental manifestation of DMD whose onset is triggered before the entry into the skeletal muscle compartment, data leading to a necessary reconsideration of dystrophin functions during muscle development.


  • Top Cited Papers
    Open Access

    Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins

    by Philippe E. Mangeot, Valérie Risson, Floriane Fusil, Aline Marnef, Emilie Laurent, Juliana Blin, Virginie Mournetas, Emmanuelle Massouridès, Thibault J. M. Sohier, Antoine Corbin, et al.

    Programmable nucleases have enabled rapid and accessible genome engineering in eukaryotic cells and living organisms. However, their delivery into target cells can be technically challenging when working with primary cells or in vivo. Here, we use engineered murine leukemia virus-like particles loaded with Cas9-sgRNA ribonucleoproteins (Nanoblades) to induce efficient genome-editing in cell lines and primary cells including human induced pluripotent stem cells, human hematopoietic stem cells and mouse bone-marrow cells. Transgene-free Nanoblades are also capable of in vivo genome-editing in mouse embryos and in the liver of injected mice. Nanoblades can be complexed with donor DNA for “all-in-one” homology-directed repair or programmed with modified Cas9 variants to mediate transcriptional up-regulation of target genes. Nanoblades preparation process is simple, relatively inexpensive and can be easily implemented in any laboratory equipped for cellular biology.


  • Open Access

    La dystrophie musculaire de Duchenne : une maladie du développement ?

    by Virginie Mournetas, Emmanuelle Massouridès, Étienne Kornobis, Hélène Polvèche, Christian Pinset

  • Open Access

    Comparability of automated human induced pluripotent stem cell culture: a pilot study

    by Peter R. T. Archibald, Amit Chandra, Dave Thomas, Olivier Chose, Emmanuelle Massouridès, Yacine Laâbi, David J. Williams

    Consistent and robust manufacturing is essential for the translation of cell therapies, and the utilisation automation throughout the manufacturing process may allow for improvements in quality control, scalability, reproducibility and economics of the process. The aim of this study was to measure and establish the comparability between alternative process steps for the culture of hiPSCs. Consequently, the effects of manual centrifugation and automated non-centrifugation process steps, performed using TAP Biosystems’ CompacT SelecT automated cell culture platform, upon the culture of a human induced pluripotent stem cell (hiPSC) line (VAX001024c07) were compared. This study, has demonstrated that comparable morphologies and cell diameters were observed in hiPSCs cultured using either manual or automated process steps. However, non-centrifugation hiPSC populations exhibited greater cell yields, greater aggregate rates, increased pluripotency marker expression, and decreased differentiation marker expression compared to centrifugation hiPSCs. A trend for decreased variability in cell yield was also observed after the utilisation of the automated process step. This study also highlights the detrimental effect of the cryopreservation and thawing processes upon the growth and characteristics of hiPSC cultures, and demonstrates that automated hiPSC manufacturing protocols can be successfully transferred between independent laboratories.


  • Open Access

    Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells

    by Emmanuelle Massouridès, Jérôme Polentes, Philippe-Emmanuel Mangeot, Virginie Mournetas, Juliette Nectoux, Nathalie Deburgrave, Patrick Nusbaum, France Leturcq, Linda Popplewell, George Dickson, et al.

    Duchenne muscular dystrophy (DMD) is a devastating X-linked recessive genetic myopathy. DMD physiopathology is still not fully understood and a prenatal onset is suspected but difficult to address. The bone morphogenetic protein 4 (BMP4) is a critical signaling molecule involved in mesoderm commitment. Human induced pluripotent stem cells (hiPSCs) from DMD and healthy individuals and human embryonic stem cells (hESCs) treated with BMP4 allowed us to model the early steps of myogenesis in normal and DMD contexts. Unexpectedly, 72h following BMP4 treatment, a new long DMD transcript was detected in all tested hiPSCs and hESCs, at levels similar to that found in adult skeletal muscle. This novel transcript named “Dp412e” has a specific untranslated first exon which is conserved only in a sub-group of anthropoids including human. The corresponding novel dystrophin protein of 412-kiloDalton (kDa), characterized by an N-terminal-truncated actin-binding domain, was detected in normal BMP4-treated hiPSCs/hESCs and in embryoid bodies. Finally, using a phosphorodiamidate morpholino oligomer (PMO) targeting the DMD exon 53, we demonstrated the feasibility of exon skipping validation with this BMP4-inducible hiPSCs model. In this study, the use of hiPSCs to analyze early phases of human development in normal and DMD contexts has led to the discovery of an embryonic 412 kDa dystrophin isoform. Deciphering the regulation process(es) and the function(s) associated to this new isoform can contribute to a better understanding of the DMD physiopathology and potential developmental defects. Moreover, the simple and robust BMP4-inducible model highlighted here, providing large amount of a long DMD transcript and the corresponding protein in only 3 days, is already well-adapted to high-throughput and high-content screening approaches. Therefore, availability of this powerful cell platform can accelerate the development, validation and improvement of DMD genetic therapies.


  • 081 Régulation de la masse et de la fonction des cellules beta par les glucocorticoïdes : implication de la sérotonine

    by J.P. Riveline, E. Massourides, A. Singh-Estivalet, B. Valtat, M. Armanet, J. Callebert, A. Bailly, A. Benecke, F. Tronche, J.F. Gautier, et al.